Provectus Biopharmaceuticals, Inc. is a clinical-stage biotech company developing immunotherapy drug candidates centered on its pharmaceutical-grade rose bengal sodium (RBS) molecule. Despite a broad patent portfolio securing its intellectual property into the late 2030s and beyond, the company continues to operate with zero commercial revenues and sustained operating losses, reflecting the high-risk profile of early-stage biotech firms. Provectus’s pipeline spans multiple indications, primarily in oncology, dermatology, and ophthalmology, but remains at early-to-mid clinical evaluation phases. The company faces substantial liquidity constraints and going concern warnings that hinge on future capital raises to continue advancing development and regulatory efforts.